+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibody Drug Conjugate Market - Global Forecast 2026-2032- Product Image
Antibody Drug Conjugate Market - Global Forecast 2026-2032- Product Image
New

Antibody Drug Conjugate Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5896370
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The antibody drug conjugate (ADC) market is undergoing substantial transformation as targeted therapies redefine oncology, placing a premium on advanced molecular precision, robust manufacturing, and strategic regulatory navigation.

Market Snapshot

The Antibody Drug Conjugate Market grew from USD 12.75 billion in 2025 to USD 14.11 billion in 2026. It is expected to continue growing at a CAGR of 10.98%, reaching USD 26.45 billion by 2032. This growth trajectory reflects expanding utilization across oncology indications and rapid innovation in payload-linker-antibody architectures, strengthening the strategic importance of ADCs across clinical and commercial pipelines.

Scope & Segmentation

This report offers a comprehensive analysis of the antibody drug conjugate market, focusing on the multifaceted interplay driving clinical and commercial value. Segmentation enables stakeholders to evaluate key technical and regional categories:

  • Payload Types: Auristatins (with notable subtypes such as MMAE and MMAF), Calicheamicins (including N‑Acetyl gamma calicheamicin), and Maytansinoids (such as DM1 and DM4) define pharmacological action and inform downstream technology choices.
  • Indications: Breast cancer (HER2-positive, triple-negative), hematological malignancies (leukemia, lymphoma, myeloma), and lung cancer are central application areas with varied disease biology and clinical demands.
  • Development Stages: Spanning preclinical, Phase I-III clinical stages, and approved products, each with unique risk profiles and regulatory requirements.
  • Linker Chemistry: Cleavable (acid, disulfide, protease-cleavable) and non-cleavable (e.g., thioether linkers) systems optimize payload release and safety.
  • Antibody Formats: Chimeric, humanized, fully human, and murine antibodies balance immunogenicity, target specificity, and manufacturability.
  • Conjugation Technologies: Conventional conjugation and site-specific approaches (enzyme-based, glycoengineering) offer better control over drug-to-antibody ratios and consistency.
  • Regional Markets: Americas, Europe Middle East & Africa, and Asia-Pacific present distinct regulatory, manufacturing, and reimbursement dynamics for ADC deployment.

Key Takeaways

  • Technical alignment among payload, linker, and antibody selection now drives clinical differentiation and commercial viability, directly affecting market access strategies.
  • Advances in site-specific conjugation and improved linker designs are enabling more predictable pharmacokinetics and lowering variability, mitigating manufacturing risk and streamlining regulatory processes.
  • Therapeutic focus is shifting beyond niche populations to encompass broader oncology use, fueled by combination regimens and adaptive program designs.
  • Regional regulatory variations require companies to generate evidence tailored for local market expectations and payer evaluation standards, impacting launch sequencing.
  • Investment in manufacturing capacity, supply chain localization, and technical partnerships is proving essential for mitigating operational risks and safeguarding clinical timelines.
  • Portfolio prioritization benefits from an integrated segmentation analysis, allowing companies to select development pathways aligned with both technical feasibility and commercial goals.

Tariff Impact

Recent U.S. tariff measures add complexity to ADC manufacturing and supply chain strategy by influencing active ingredient sourcing and equipment procurement. Contract development and manufacturing organizations, as well as sponsors, face new decisions regarding nearshoring, supplier diversification, and inventory management. These pressures can trigger renegotiation of strategic partnerships, require supply chain reconfiguration, and necessitate closer alignment with regulatory agencies as production sites or manufacturing approaches shift. Enhanced supply chain resilience and the adoption of process improvements may help mitigate tariff-induced risks but demand additional investment and technical validation.

Methodology & Data Sources

This report synthesizes peer-reviewed scientific literature, regulatory documents, expert interviews, and facility capability analyses. Insights were validated through triangulation of multiple independent sources, including primary input from clinical and manufacturing specialists, to ensure technical accuracy and practical relevance.

Why This Report Matters

  • Empowers senior leaders to assess technical, regulatory, and operational imperatives shaping ADC market opportunities.
  • Provides actionable insights to inform partnership strategies, supply chain decisions, and clinical development investments across global markets.
  • Offers a framework to integrate technical trends and strategic segmentation, enabling data-driven portfolio prioritization.

The Antibody Drug Conjugate Market: Integrated Strategies Define Success

Success in the antibody drug conjugate market will depend on the alignment of innovation, operational excellence, and regional adaptation. Organizations that invest in platform technology, resilient supply chains, and adaptive clinical approaches will be best positioned to realize the full potential of ADCs in oncology.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Antibody Drug Conjugate Market, by Target Antigen
8.1. CD30
8.2. CD79B
8.3. HER2
8.4. Nectin 4
8.5. Trop-2
9. Antibody Drug Conjugate Market, by Linker Type
9.1. Cleavable
9.1.1. Acid-Labile
9.1.2. Disulfide-Reducible
9.1.3. Enzymatically Cleavable
9.2. Non-Cleavable
10. Antibody Drug Conjugate Market, by Antibody Type
10.1. Antibody Fragments
10.2. Bispecific Antibodies
10.3. Monoclonal Antibodies
11. Antibody Drug Conjugate Market, by Drug Type
11.1. Belantamab Mafodotin
11.2. Brentuximab Vedotin
11.3. Polatuzumab Vedotin
11.4. Sacituzumab Govitecan
11.5. Trastuzumab Deruxtecan
11.6. Trastuzumab Emtansine
12. Antibody Drug Conjugate Market, by Payload Type
12.1. DNA-Damaging Agents
12.2. Topoisomerase Inhibitors
12.3. Tubulin Inhibitors
13. Antibody Drug Conjugate Market, by Development Stage
13.1. Approved/Commercialized
13.2. Phase I
13.3. Phase II
13.4. Phase III
13.5. Preclinical
14. Antibody Drug Conjugate Market, by Indication
14.1. Bladder Cancer
14.2. Blood Cancer
14.3. Breast Cancer
14.4. Lymphoma
14.5. Multiple Myeloma
14.6. Urothelial Cancer
15. Antibody Drug Conjugate Market, by End User
15.1. Academic & Research Institutes
15.2. Ambulatory Surgical Centers
15.3. Biopharmaceutical & Biotechnology Companies
15.4. Hospitals
15.5. Specialty Cancer Clinics
16. Antibody Drug Conjugate Market, by Region
16.1. Americas
16.1.1. North America
16.1.2. Latin America
16.2. Europe, Middle East & Africa
16.2.1. Europe
16.2.2. Middle East
16.2.3. Africa
16.3. Asia-Pacific
17. Antibody Drug Conjugate Market, by Group
17.1. ASEAN
17.2. GCC
17.3. European Union
17.4. BRICS
17.5. G7
17.6. NATO
18. Antibody Drug Conjugate Market, by Country
18.1. United States
18.2. Canada
18.3. Mexico
18.4. Brazil
18.5. United Kingdom
18.6. Germany
18.7. France
18.8. Russia
18.9. Italy
18.10. Spain
18.11. China
18.12. India
18.13. Japan
18.14. Australia
18.15. South Korea
19. United States Antibody Drug Conjugate Market
20. China Antibody Drug Conjugate Market
21. Competitive Landscape
21.1. Market Concentration Analysis, 2025
21.1.1. Concentration Ratio (CR)
21.1.2. Herfindahl Hirschman Index (HHI)
21.2. Recent Developments & Impact Analysis, 2025
21.3. Product Portfolio Analysis, 2025
21.4. Benchmarking Analysis, 2025
21.5. Abbvie Inc.
21.6. ADC Therapeutics S.A.
21.7. Amgen Inc.
21.8. Astellas Pharma Inc.
21.9. AstraZeneca PLC
21.10. Bristol-Myers Squibb Company
21.11. Cambrex Corporation
21.12. Celldex Therapeutics Inc.
21.13. Creative Biolabs, Inc.
21.14. Daiichi Sankyo Company, Limited
21.15. Duality Biologics
21.16. F. Hoffmann-La Roche Ltd.
21.17. Gilead Sciences, Inc.
21.18. GlaxoSmithKline PLC
21.19. ImmunoGen, Inc.
21.20. Innate Pharma SA
21.21. Innovent Biologics, Inc.
21.22. Johnson & Johnson Innovation LLC
21.23. LIGACHEM BIOSCIENCES Inc.
21.24. Merck KGaA
21.25. Mersana Therapeutics, Inc.
21.26. NJ Bio Inc.
21.27. Novartis AG
21.28. Oxford BioTherapeutics
21.29. Pfizer, Inc.
21.30. Pheon Therapeutics
21.31. Piramal Pharma Solutions
21.32. Recipharm AB
21.33. Sanofi S.A.
21.34. Sorrento Therapeutics, Inc.
21.35. Takeda Pharmaceutical Company Ltd.
List of Figures
FIGURE 1. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 15. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 16. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD79B, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD79B, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD79B, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HER2, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HER2, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HER2, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NECTIN 4, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NECTIN 4, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NECTIN 4, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TROP-2, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TROP-2, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TROP-2, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACID-LABILE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACID-LABILE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACID-LABILE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DISULFIDE-REDUCIBLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DISULFIDE-REDUCIBLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DISULFIDE-REDUCIBLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENZYMATICALLY CLEAVABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENZYMATICALLY CLEAVABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENZYMATICALLY CLEAVABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY FRAGMENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY FRAGMENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY FRAGMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BELANTAMAB MAFODOTIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BELANTAMAB MAFODOTIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BELANTAMAB MAFODOTIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY POLATUZUMAB VEDOTIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY POLATUZUMAB VEDOTIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY POLATUZUMAB VEDOTIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SACITUZUMAB GOVITECAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SACITUZUMAB GOVITECAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SACITUZUMAB GOVITECAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRASTUZUMAB DERUXTECAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRASTUZUMAB DERUXTECAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRASTUZUMAB DERUXTECAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRASTUZUMAB EMTANSINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRASTUZUMAB EMTANSINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRASTUZUMAB EMTANSINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DNA-DAMAGING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DNA-DAMAGING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DNA-DAMAGING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TUBULIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TUBULIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TUBULIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPROVED/COMMERCIALIZED, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPROVED/COMMERCIALIZED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPROVED/COMMERCIALIZED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLADDER CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALTY CANCER CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALTY CANCER CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALTY CANCER CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 127. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 128. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 129. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 130. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 131. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 132. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 133. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 134. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 135. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. EUROPE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 167. EUROPE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 168. EUROPE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 169. EUROPE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 170. EUROPE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 171. EUROPE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 172. EUROPE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 173. EUROPE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 174. EUROPE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 175. EUROPE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 184. MIDDLE EAST ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 186. AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 188. AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 189. AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 190. AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 191. AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 192. AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 193. AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 194. AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 195. AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 207. ASEAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. ASEAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 209. ASEAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 210. ASEAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 211. ASEAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 212. ASEAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 213. ASEAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 214. ASEAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 215. ASEAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 216. ASEAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 217. GCC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 218. GCC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 219. GCC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 220. GCC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 221. GCC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 222. GCC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 223. GCC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 224. GCC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 225. GCC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 226. GCC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 237. BRICS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 238. BRICS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 239. BRICS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 240. BRICS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 241. BRICS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 242. BRICS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 243. BRICS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 244. BRICS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 245. BRICS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 246. BRICS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 247. G7 ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 248. G7 ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 249. G7 ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 250. G7 ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 251. G7 ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 252. G7 ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 253. G7 ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 254. G7 ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 255. G7 ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 256. G7 ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 257. NATO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 258. NATO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 259. NATO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 260. NATO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 261. NATO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 262. NATO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 263. NATO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 264. NATO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 265. NATO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 266. NATO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 267. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 268. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 269. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 270. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 271. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 272. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 273. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 274. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 275. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 276. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 277. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 278. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 279. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
TABLE 280. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKER TYPE, 2018-2032 (USD MILLION)
TABLE 281. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE, 2018-2032 (USD MILLION)
TABLE 282. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ANTIBODY TYPE, 2018-2032 (USD MILLION)
TABLE 283. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 284. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PAYLOAD TYPE, 2018-2032 (USD MILLION)
TABLE 285. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
TABLE 286. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 287. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Antibody Drug Conjugate market report include:
  • Abbvie Inc.
  • ADC Therapeutics S.A.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Cambrex Corporation
  • Celldex Therapeutics Inc.
  • Creative Biolabs, Inc.
  • Daiichi Sankyo Company, Limited
  • Duality Biologics
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • ImmunoGen, Inc.
  • Innate Pharma SA
  • Innovent Biologics, Inc.
  • Johnson & Johnson Innovation LLC
  • LIGACHEM BIOSCIENCES Inc.
  • Merck KGaA
  • Mersana Therapeutics, Inc.
  • NJ Bio Inc.
  • Novartis AG
  • Oxford BioTherapeutics
  • Pfizer, Inc.
  • Pheon Therapeutics
  • Piramal Pharma Solutions
  • Recipharm AB
  • Sanofi S.A.
  • Sorrento Therapeutics, Inc.
  • Takeda Pharmaceutical Company Ltd.

Table Information

Report AttributeDetails
No. of Pages199
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 14.11 Billion
Forecasted Market Value ( USD ) by 2032 $ 26.45 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Antibody-drug Conjugates for Tumors Market - Global Forecast 2025-2030 - Product Image

Antibody-drug Conjugates for Tumors Market - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Antibody Drug Conjugate - Competitive Landscape, 2025 - Product Image

Antibody Drug Conjugate - Competitive Landscape, 2025

  • Report
  • 450 Pages
  • Global
From
Global Antibody Drug Conjugates Market - 2025-2035: Focus on Product, Application, Target, Payload Type, Linker Type, Linker Technology, and Geography - Product Image

Global Antibody Drug Conjugates Market - 2025-2035: Focus on Product, Application, Target, Payload Type, Linker Type, Linker Technology, and Geography

  • Report
  • Global
From
Antibody Drug Conjugates Market Size, Share & Trends Analysis Report by Application (Blood Cancer, Urothelial Carcinoma, Ovarian Cancer, Breast Cancer, Other Cancer), Product, Payload, Technology, Distribution Channel and Region with Growth Forecasts, 2025-2033 - Product Image

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report by Application (Blood Cancer, Urothelial Carcinoma, Ovarian Cancer, Breast Cancer, Other Cancer), Product, Payload, Technology, Distribution Channel and Region with Growth Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From
Antibody Drug Conjugates Contract Manufacturing Market - Global Forecast 2026-2032 - Product Image

Antibody Drug Conjugates Contract Manufacturing Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.